Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange 11:31:47 2024-06-25 am EDT 5-day change 1st Jan Change
253.4 CHF -0.78% Intraday chart for Roche Holding AG +2.22% +3.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Halozyme Therapeutics Says Roche's OCREVUS SC With ENHANZE Gets European Commission Approval MT
Roche: approval of Ocrevus SC in Europe CF
Roche Wins EU Nod for Subcutaneous Formula of Multiple Sclerosis Drug Ocrevus MT
Roche's Multiple Sclerosis Injection Gets EU Approval DJ
Halozyme Therapeutics, Inc. Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis CI
Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis CI
Swiss Market Index in Green as Investors Keep Eye on European Politics MT
Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm... Our Logo
Foreign banks target Switzerland after UBS takeover of Credit Suisse RE
ROCHE HOLDINGS AG : Barclays reiterates its Neutral rating ZD
Roche: two new units for cobas pro CF
Roche: marketing authorization application validated for Elevidys in Europe CF
European Medicines Agency Begins Review of Roche's Gene Therapy for Duchenne Muscular Dystrophy MT
US FDA approves Roche's drug for a chronic blood disorder RE
Nykredit Bank Initiates Coverage on Roche With Buy Recommendation MT
Nykredit Bank Starts Roche Coverage at Buy MT
Sarepta Therapeutics Gets Expanded Label FDA Approval for Duchenne Muscular Dystrophy; Shares Soar Premarket MT
Sarepta Therapeutics Gets Expanded US FDA Approval for Treatment of Duchenne Muscular Dystrophy; Shares Soar After Hours MT
US FDA approves expanded use of Sarepta's Duchenne gene therapy; shares jump RE
Sarepta Shares Soar 37% Following Expanded Approval for Elevidys DJ
Sarepta Therapeutics, Inc. Announces Expanded US FDA Approval of Eletidys to Duchenne Muscular Dystrophy Patients Ages 4 and Above CI
ROCHE HOLDINGS AG : UBS reiterates its Neutral rating ZD
Swiss Equities Close Higher as SNB Delivers Another Rate Cut MT
Roche: new detection test for lymphoma CF
Roche Launches First Clinically Approved Test for B-cell Lymphoma MT
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
255.4 CHF
Average target price
278.1 CHF
Spread / Average Target
+8.87%
Consensus
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. News Roche Holding AG
  5. Roche Gains as Weight-loss Injection Shows Potential in Early-stage Study